Pratt, Wylce & Lords, Ltd. Discloses Terms Of Immune Technology, Inc. Acquisition.HILTON HEAD ISLAND Hilton Head Island An island off the southern coast of South Carolina in the Sea Islands of the Atlantic Ocean. It is a popular tourist resort. The town of Hilton Head Island, on the northeast coast, has a population of 35,200. , S.C.--(BW HealthWire)--Nov. 21, 1997-- Hilton Head Island, SC - Pratt, Wylce & Lords, Ltd. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB: PWLS PWLS Pop Warner Little Scholars Inc ) disclosed today the terms of its acquisition of 100% of the assets of Immune Technologies, Inc. (ITI (Information Technology Industry Council, Washington, DC, www.itic.org) Formerly the Computer and Business Equipment Manufacturers Association (CBEMA), founded in 1916. ITI is a membership organization composed of approximately 30 large high-tech companies. ) a privately held Nevada Corporation headquartered in Columbus, Georgia. The agreement, which requires the approval of a majority of shareholders from both companies, calls for a purchase price of 2,000,000 shares of Pratt, Wylce & Lords, Ltd. common stock. There are currently approximately 3,100,000 shares of Pratt, Wylce & Lords, Ltd. stock outstanding. ITI owns the exclusive world wide rights to manufacture and market products developed from the Immune Modulating Technology developed by Lea Dowd, the inventor of the product and Vice President of Research for ITI. The products will be marketed under the trade name "I-MOD I-MOD Infinity Modulator (Star Trek) (TM)". To date, ITI has successfully completed clinical trials on their "I-MOD ER(TM)" product for the treatment of respiratory infections in horses. Utilization as an adjuvant to conventional treatment for respiratory infections in horses is one application this product has. Once an agreement is reached with a manufacturer, the company will produce the required test batches and file its final application for product approval to the USDA USDA, n.pr See United States Department of Agriculture. . ITI has also begun recruiting clinical investigators for the canine dermatological product "I-MOD CD(TM)". "I-MOD CD(TM)" is designed to treat canine demodectic mange and chronic bacterial dermatitis. Subsequently, ITI will begin formulation of "I-MOD BM(TM)" which will be designed to treat mastitis mastitis (măstī`tĭs), inflammation of the breast. Mastitis most commonly occurs in nursing mothers between the first and third weeks after childbirth, usually of the first child. in dairy cows and "I-MOD BR(TM)" which will be directed toward the treatment of respiratory disease in cattle. According to Ms. Dowd, "As pleased as we are with the results of the clinical trials, demonstrating "I-MOD ER(TM)'s" efficacy as a cure, we are anxious to demonstrate the technology's effectiveness as a disease preventative. It just makes sense to strengthen the immune system in order to prevent microbes from taking hold rather than waiting for the disease to manifest itself prior to beginning treatment." CONTACT: Pratt, Wylce & Lords, Ltd. 803/686-5590 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion